Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYTK NASDAQ:KOD NASDAQ:KRYS NASDAQ:NUVL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTKCytokinetics$71.48-1.1%$69.97$31.99▼$80.20$9.00B0.422.13 million shs1.61 million shsKODKodiak Sciences$31.05-9.1%$39.92$3.43▼$47.84$2.14B2.21638,104 shs1.45 million shsKRYSKrystal Biotech$301.00-2.2%$282.39$127.99▼$319.48$9.07B0.53253,228 shs264,305 shsNUVLNuvalent$90.95-3.3%$102.57$71.13▼$113.01$7.43B1.15773,456 shs716,007 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTKCytokinetics+2.23%-5.88%-6.23%+19.67%+123.05%KODKodiak Sciences+0.86%-5.43%-19.92%+37.41%+760.45%KRYSKrystal Biotech+1.98%-0.81%+8.16%+21.33%+133.12%NUVLNuvalent+4.26%-13.96%-7.34%-5.42%+22.39%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTKCytokinetics$71.48-1.1%$69.97$31.99▼$80.20$9.00B0.422.13 million shs1.61 million shsKODKodiak Sciences$31.05-9.1%$39.92$3.43▼$47.84$2.14B2.21638,104 shs1.45 million shsKRYSKrystal Biotech$301.00-2.2%$282.39$127.99▼$319.48$9.07B0.53253,228 shs264,305 shsNUVLNuvalent$90.95-3.3%$102.57$71.13▼$113.01$7.43B1.15773,456 shs716,007 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTKCytokinetics+2.23%-5.88%-6.23%+19.67%+123.05%KODKodiak Sciences+0.86%-5.43%-19.92%+37.41%+760.45%KRYSKrystal Biotech+1.98%-0.81%+8.16%+21.33%+133.12%NUVLNuvalent+4.26%-13.96%-7.34%-5.42%+22.39%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYTKCytokinetics 2.86Moderate Buy$99.3040.08% UpsideKODKodiak Sciences 2.63Moderate Buy$42.1439.11% UpsideKRYSKrystal Biotech 2.83Moderate Buy$324.117.23% UpsideNUVLNuvalent 2.94Moderate Buy$141.2455.00% UpsideCurrent Analyst Ratings BreakdownLatest KOD, CYTK, KRYS, and NUVL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026NUVLNuvalent Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$165.006/2/2026NUVLNuvalent Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight6/1/2026KRYSKrystal Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$310.005/28/2026NUVLNuvalent WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$125.005/21/2026NUVLNuvalent Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$189.005/21/2026NUVLNuvalent Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$189.005/21/2026NUVLNuvalent Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/18/2026CYTKCytokinetics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform ➝ Buy$99.005/18/2026CYTKCytokinetics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy5/18/2026KRYSKrystal Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$310.005/12/2026CYTKCytokinetics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$92.00 ➝ $97.00(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYTKCytokinetics$105.82M83.36N/AN/A($5.39) per share-13.15KODKodiak SciencesN/AN/AN/AN/A$2.97 per shareN/AKRYSKrystal Biotech$417.30M21.35$7.30 per share41.40$42.06 per share7.19NUVLNuvalentN/AN/AN/AN/A$15.95 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYTKCytokinetics-$784.96M-$6.84N/AN/AN/A-784.02%N/A-52.86%8/6/2026 (Estimated)KODKodiak Sciences-$229.97M-$4.17N/AN/AN/AN/A-253.85%-81.48%8/12/2026 (Estimated)KRYSKrystal Biotech$204.83M$7.4840.4128.73N/A53.92%19.25%17.62%8/3/2026 (Estimated)NUVLNuvalent-$425.38M-$6.06N/AN/AN/AN/A-40.11%-35.43%8/6/2026 (Estimated)Latest KOD, CYTK, KRYS, and NUVL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q4 2025KODKodiak Sciences-$0.93-$0.94-$0.01-$0.94N/AN/A5/7/2026Q1 2026NUVLNuvalent-$1.35-$1.39-$0.04-$1.39$0.49 millionN/A5/5/2026Q1 2026CYTKCytokinetics-$1.67-$1.67N/A-$1.67$8.52 million$19.36 million5/4/2026Q1 2026KRYSKrystal Biotech$1.45$1.83+$0.38$1.83$112.11 million$116.36 million3/31/2026Q4 2025KODKodiak Sciences-$1.02-$1.04-$0.02-$1.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCYTKCytokineticsN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYTKCytokineticsN/A4.214.21KODKodiak SciencesN/A3.543.54KRYSKrystal BiotechN/A9.469.06NUVLNuvalentN/A16.1416.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYTKCytokineticsN/AKODKodiak Sciences89.06%KRYSKrystal Biotech86.29%NUVLNuvalent97.26%Insider OwnershipCompanyInsider OwnershipCYTKCytokinetics2.60%KODKodiak Sciences45.90%KRYSKrystal Biotech13.10%NUVLNuvalent5.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYTKCytokinetics250124.43 million121.20 millionOptionableKODKodiak Sciences9062.58 million33.86 millionOptionableKRYSKrystal Biotech21029.48 million25.62 millionOptionableNUVLNuvalent4079.00 million75.03 millionOptionableKOD, CYTK, KRYS, and NUVL HeadlinesRecent News About These CompaniesStifel Nicolaus Sticks to Their Buy Rating for Nuvalent (NUVL)June 5 at 9:50 AM | theglobeandmail.comNuvalent (NASDAQ:NUVL) CFO Sells $1,128,026.70 in StockJune 4 at 7:30 AM | insidertrades.comGoldman Sachs Sticks to Its Buy Rating for Nuvalent (NUVL)June 3 at 9:40 AM | theglobeandmail.comNuvalent (NASDAQ:NUVL) Insider Deborah Ann Miller Sells 5,500 Shares of StockJune 3 at 4:04 AM | americanbankingnews.comDeborah Ann Miller Sells 5,500 Shares of Nuvalent (NASDAQ:NUVL) StockJune 2 at 4:33 AM | insidertrades.comNuvalent Eyes Two Lung Cancer Drug Launches as FDA Grants Priority ReviewJune 1, 2026 | americanbankingnews.comNuvalent, Inc. (NASDAQ:NUVL) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 31, 2026 | americanbankingnews.comNuvalent, Inc. (NASDAQ:NUVL) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 31, 2026 | marketbeat.comNuvalent's (NUVL) Outperform Rating Reiterated at WedbushMay 28, 2026 | marketbeat.comNuvalent granted FDA priority review for lung cancer therapyMay 27, 2026 | msn.comNuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLCMay 27, 2026 | prnewswire.comBernstein initiates coverage of Nuvalent (NUVL) with outperform recommendationMay 23, 2026 | msn.comNuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual MeetingMay 21, 2026 | prnewswire.comGuggenheim Sticks to Their Buy Rating for Nuvalent (NUVL)May 15, 2026 | theglobeandmail.comState of New Jersey Common Pension Fund D Sells 15,228 Shares of Nuvalent, Inc. $NUVLMay 11, 2026 | marketbeat.comUBS Group AG Acquires 185,932 Shares of Nuvalent, Inc. $NUVLMay 8, 2026 | marketbeat.comNuvalent (NASDAQ:NUVL) Announces Quarterly Earnings ResultsMay 7, 2026 | marketbeat.comNuvalent (NASDAQ:NUVL) CEO Sells $3,050,700.00 in StockMay 7, 2026 | insidertrades.comNuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial ResultsMay 7, 2026 | prnewswire.comComerica Bank Grows Holdings in Nuvalent, Inc. $NUVLMay 7, 2026 | marketbeat.comCanaccord Genuity Sticks to Their Buy Rating for Nuvalent (NUVL)May 6, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKOD, CYTK, KRYS, and NUVL Company DescriptionsCytokinetics NASDAQ:CYTK$71.48 -0.81 (-1.12%) Closing price 04:00 PM EasternExtended Trading$71.32 -0.17 (-0.23%) As of 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Kodiak Sciences NASDAQ:KOD$31.05 -3.11 (-9.10%) Closing price 04:00 PM EasternExtended Trading$30.46 -0.60 (-1.92%) As of 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.Krystal Biotech NASDAQ:KRYS$301.00 -6.79 (-2.21%) Closing price 04:00 PM EasternExtended Trading$303.00 +2.00 (+0.66%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Nuvalent NASDAQ:NUVL$90.95 -3.07 (-3.27%) Closing price 04:00 PM EasternExtended Trading$90.93 -0.02 (-0.02%) As of 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
